Our findings not only provide new insights into the molecular mechanisms driving chemoresistance in CRC but also identify WBP1 as a promising therapeutic target for chemoresistant CRC treatment through the modulation of mitochondrial function and ferroptosis. The gene discussed is WBP1; the disease is colorectal carcinoma.